“GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.” Boston, Jan. 30, 2026 (GLOBE ...

MetaVia begins patient dosing in Part 3 of phase 1 study of DA-1726, a GLP-1 and glucagon dual agonist to treat obesity: Cambridge, Massachusetts Monday, April 13, 2026, 11:00 Hrs ...

Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

What will the future world of GLP-1 drugs look like? From Eli Lilly's Foundayo to triple-strength Wegovy, discover the ...

While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule ...

A study shows FGF21 acts on specific brain regions to increase metabolism and reduce weight, revealing a distinct mechanism from existing obesity drugs, and enabling targeted treatments.

Eli Lilly and Company LLY, last week, gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill ...

Researchers map the peptide behind semaglutide across 25 brain regions in each sex, finding striking differences in appetite and reward circuits. GLP-1 analogs, used to treat obesity, are among the ...

Then, this natural GLP-1 seems like a key to preventing both diabetes and obesity, but it disappears too quickly in the body. The story of flooding the body with "analog" keys to "act" and restart ...

From legacy therapeutics to next-generation GLP-1s, advances in synthesis, analysis, and regulation are reshaping how peptide ...

A hormone that can reverse obesity in mice is offering new clues about how the brain controls body weight. Researchers at the ...